Current Modalities in Soft-Tissue Reconstruction and Vascularized Adipose Engineering.
El-Mallah JC., Wen C., Waldron O., Jikaria NR., Asgardoon MH., Schlidt K.
Narrative Review, published in Biomolecules (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Biomolecules (2025)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40563421
- PMCID
- PMC12190677
- DOI
- 10.3390/biom15060780
- Citations
- 3
Abstract (original English)
Soft-tissue loss resulting from trauma or oncologic resection is a significant problem worldwide. Surgical reconstruction using adipose tissue has long been the gold-standard solution. However, these surgeries are often highly morbid, not always feasible in patients with insufficient adipose, and can have unpredictable results. Engineered soft-tissue replacements present a promising alternative. Many cell types, such as adipose-derived stem cells, have been recognized as a viable starting platform upon which new avenues in tissue engineering can be built. Additionally, efforts to develop scaffolds that can mimic the native extracellular matrix have been made with varying success. However, the suboptimal vascularization of engineered replacements is still a major limiting factor for achieving clinical translation. The current research explores the integration of all these techniques, including the use of growth factors, bioactive molecules, and advanced microsurgical techniques to enhance the vascularization process. This translational review covers the clinically standard methods of soft-tissue reconstruction and dives into emerging engineering techniques to develop vascularized adipose alternatives.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.